Once again, the results indicate that continued treatment with AZP-3813 translates into high effectiveness in suppressing IGF-I levels in vivo in normal beagle dogs, supporting its potential role in acromegaly medical therapy. This evidence concerns the gene IGF1 and acromegaly.